Britt Meelby Jensen
President and Chief Executive Officer (CEO)
Britt Meelby Jensen (Danish, born 1973) joined Zealand as CEO in January 2015. Prior to joining Zealand, she headed the world leading Agilent-owned Danish diagnostics company, Dako, as the company’s CEO.
Britt has extensive experience from a range of managerial positions within the life science industry, including 11 years of international experience from Novo Nordisk. At Novo Nordisk, she held various positions, including head of Global Marketing Nordic, Global Diabetes Lifecycle Management, prelaunch commercial projects and more recently Corporate Vice President for Global Marketing, Market Access and Commercial Excellence.
Previously, Britt has worked for McKinsey and Company and within the EU Institutions in Brussels. She has a M.Sc. in International Marketing Management from Copenhagen Business School, Denmark and an MBA from Solvay Business School in Brussels, Belgium.
Senior Vice President and Chief Financial Officer (CFO)
Mats Blom (Swedish, born 1965) joined Zealand as CFO in March 2010. Prior to joining Zealand, Mats served as Chief Financial Officer at Swedish Orphan International a leading European orphan drug company acquired by BioVitrum of Sweden in 2009 (now Sobi Pharmaceuticals).
Mats has extensive managerial experience and he has held CFO positions at Active Biotech and Anoto both publicly listed on Nasdaq Stockholm stock exchange Previously, Mats has worked several years as a management consultant at Gemini Consulting and at Ernst & Young’s Transaction Services division.
Mats hold a BA in Business Administration and Economics from the University of Lund followed by an MBA from IESE University of Navarra, Barcelona.
Mats is Chairman of the board for Medical Need AB.
Senior Vice President, Chief Medical and Development Officer
Adam Steensberg (Danish, born 1974) joined Zealand in 2010 as Head of Clinical Development. Since 2011 he has been leading all development activities and was promoted to Senior Vice President and Chief Medical and Development Officer in March 2015.
Prior to joining Zealand, Adam has led several clinical research teams as medical director at Novo Nordisk A/S, and he has experience as clinician from the University hospital of Copenhagen. Adam has extensive managerial experience and he has served as medical and scientific advisor within endocrinology, cardiology, gastroenterology, and rheumatology. He has significant experience with leading regulatory strategies and he has been instrumental in implementing a patient-centric discovery and development process at Zealand. Adam has published more than 45 peer-reviewed scientific papers in international journals.
Adam holds a Doctor of medicine followed by a Doctor of Medical Science (DMSc/ dr.med) from University of Copenhagen and an MBA from IMD, Switzerland.
Hanne Leth Hillman
Senior Vice President, Investor Relations & Communications
Hanne Leth Hillman (Danish, born 1965) joined Zealand as Vice President for IR and Corporate Communications in 2011 and she was promoted to Senior Vice President in 2015. Prior to joining Zealand, Hanne served for more than five years in positions with responsibility for Investor Relations, Financial Market relations and Corporate Communications in two other publicly listed biotech companies.
Hanne also has ten years of broad-based experience from positions related to Life Sciences investment banking, including positions in equity research, asset management and corporate finance.
Hanne holds a Master in Business Administration and International Finance from the Aarhus University School of Business. She has studied International Economics at the University of Montréal’s Business School (École des Hautes Études Commerciale) in Montreal, Canada and studied also at the Business School of Marseille, École Superieure de Commerce in France.
Hanne is Vice Chairman of the Board of Directors of the Danish Investor Relations Association (DIRF).
Senior Vice President, Chief Science Officer
Andrew Parker (1965, British) joined Zealand in July 2016. Andrew comes from a position as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2 & Cie SCPC in Switzerland. In parallel, he has held the position as CEO for Arisgen SA (an Eclosion2 portfolio company developing an oral peptide drug delivery technology).
Andrew has more than twenty years of experience from senior leadership and managerial positions in international pharmaceutical, biotech and start-up companies, including several years with Shire Pharmaceuticals, Opsona Therapeutics, and AstraZeneca to mention a few.
He holds a Ph.D. from the National Institute for Medical Research at Mill Hill, London, conducted post-doctoral research at Johns Hopkins Medical School, Baltimore, USA, and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 scientific articles in renowned international journals.